Sunshine Biopharma Enters the $2.8 Billion Global Dienogest Market with Canadian Regulatory Approval

* Dienogest is first-line therapy for pelvic pain associate with endometriosis * The endometriosis treatment market is projected to reach $5.2 billion by 2034

FORT LAUDERDALE, FL / ACCESS Newswire / August 4, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medications, is pleased to announce the approval of its generic Dienogest tablets of 2mg for the Canadian market. Dienogest is the generic equivalent of the brand name, Visanne(®).